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Complex neuroadaptations within key nodes of the brain’s “reward circuitry” are thought
to underpin long-term vulnerability to relapse. A more comprehensive understanding of
the molecular and cellular signaling events that subserve relapse vulnerability may lead to
pharmacological treatments that could improve treatment outcomes for psychostimulant-
addicted individuals. Recent advances in this regard include ﬁndings that drug-induced
perturbations to neurotrophin, metabotropic glutamate receptor, and dopamine receptor
signaling pathways perpetuate plasticity impairments at excitatory glutamatergic synapses
on ventral tegmental area and nucleus accumbens neurons. In the context of addiction,
much previous work, in terms of downstream effectors to these receptor systems, has
centered on the extracellular-regulated MAP kinase signaling pathway. The purpose of the
present review is to highlight the evidence of an emerging role for another downstream
effector of these addiction-relevant receptor systems – themammalian target of rapamycin
complex 1 (mTORC1). mTORC1 functions to regulate synaptic protein translation and is a
potential critical link in our understanding of the neurobiological processes that drive addic-
tion and relapse behavior. The precise cellular and molecular changes that are regulated
by mTORC1 and contribute to relapse vulnerability are only just coming to light.Therefore,
we aim to highlight evidence that mTORC1 signaling may be dysregulated by drug expo-
sure and that these changes may contribute to aberrant translation of synaptic proteins
that appear critical to increased relapse vulnerability, including AMPARs. The importance
of understanding the role of this signaling pathway in the development of addiction vulnera-
bility is underscored by the fact that themTORC1 inhibitor rapamycin reduces drug-seeking
in pre-clinical models and preliminary evidence indicating that rapamycin suppresses drug
craving in humans.
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INTRODUCTION
Drug addiction is a complex neuropsychiatric condition with the
risk of relapse after quitting considered a fundamental obstacle
to long-term treatment management (O’Brien, 2005; Kalivas and
O’Brien, 2008). Despite signiﬁcant recent efforts, our understand-
ing of the neurobiological processes that lead to addiction, and
subsequently protracted relapse risk, is inadequate to the point
that there has been limited translation of pre-clinical ﬁndings into
pharmacological treatments for this condition. Critically, further
research is required to unravel the complex neuroadpatations that
cause psychostimulant addiction, in particular the molecular and
cellular signaling events that underpin protracted vulnerability
to relapse. This review will focus on recent ﬁndings relevant to
translational efforts to identify targets to treat psychostimulant
addiction.
The brain circuitry that controls drug-seeking and relapse is
multi-nodal (Koob and Volkow, 2009), however, the two nodes
that have received the most attention with regard to functional
and molecular correlates of addiction are the ventral tegmental
area (VTA) A10 dopamine neurons and the nucleus accumbens
(NAC; Kauer and Malenka, 2007; Kalivas and O’Brien, 2008;
Luscher and Malenka, 2011). Although other brain regions, such
as the prefrontal cortex (PFC), amygdala, and dorsal striatum,
are also known to play important roles in addiction, our under-
standing of the pre- and post-synaptic neuroadaptations that
occur within the VTA and NAC is signiﬁcantly more detailed
than these other major nodes in the brain “relapse circuit” (Kali-
vas and O’Brien, 2008). Furthermore, the NAC and VTA have
been ascribed an important role in reward learning (Stuber
et al., 2008; Tsai et al., 2009) and drug-induced synaptic plas-
ticity deﬁcits in these brain regions that occur in response to
chronic drug taking have been hypothesized to impede the learn-
ing of new strategies to overcome addiction (Martin et al., 2006;
Kalivas and Volkow, 2011). (We direct readers to several excel-
lent recent reviews describing the effects of chronic cocaine self-
administration on synaptic plasticity within the VTA and NAC;
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Kauer and Malenka, 2007; Kalivas and O’Brien, 2008; Luscher and
Malenka, 2011).
Given their importance, signiﬁcant research efforts have been,
and continue to be, directed at the VTA and NAC in order
to improve our understanding of the molecular signaling path-
ways that are responsible for the drug-induced maladaptations.
Advances in these areas have highlighted a role for a number
of signaling pathways in the development of addiction (Grimm
et al., 2003; Lu et al., 2006; Graham et al., 2007; Dietz et al., 2009;
Russo et al., 2009; McGinty et al., 2010; Duncan and Lawrence,
2011) including molecules downstream of neurotrophin (NTrk),
metabotropic glutamate (mGluR), and dopamine (DR) recep-
tors. Drug-induced perturbations in these signaling pathways are
thought to perpetuate plasticity impairments at excitatory glu-
tamatergic synapses on VTA and NAC neurons. The purpose of
the present review is to highlight the emerging evidence that the
mammalian target of rapamycin complex 1 (mTORC1), a down-
stream target of these receptor signaling pathways that regulate
synaptic protein translation, is a potentially critical link in our
understanding of the neurobiological processes that drive addic-
tion and relapse behavior (Neasta et al., 2010; Wang et al., 2010;
Brown et al., 2011). Investigations of mTOR’s role in addiction
are presently limited to the NAC and VTA, and consequently our
review will outline relevant molecular and cellular adaptations
within these structures. However, where necessary we will draw
mechanistic links derived from studies assessing the role of mTOR
in synaptic plasticity in other brain regions. We begin by brieﬂy
summarizing mTORC1 signaling in the CNS, however, we alert
readers to a number of important reviews that have recently been
published on this topic (Klann et al., 2004; Costa-Mattioli et al.,
2009; Richter and Klann, 2009; Hoeffer and Klann, 2010; Sharma
et al., 2010).
AN OVERVIEW OF mTORC1 SIGNALING WITHIN THE BRAIN
Mammalian target of rapamycin (mTOR) is a 250-kDa ser-
ine/threonine protein kinase. Much of what we know about
mTOR signaling is based on the effects of the speciﬁc inhibitor,
rapamycin, a macroclide (sirolimus) originally identiﬁed in a soil
bacterium. Rapamycin acts by binding to the cytosolic protein
FKBP12, which leads to the displacement of Raptor from mTOR
(Lorenz andHeitman,1995; Sabers et al., 1995). Raptor is critical to
mTOR function (Kim et al., 2002) and the complex between these
two proteins, together with proline-rich AKT substrate 40 kDa
(PRAS40), mammalian lethal with Sec13 protein 8 (mLST8), and
DEP-domain-containing mTOR interacting protein (Deptor), is
referred to as mTOR complex 1 (mTORC1; Hoeffer and Klann,
2010). Rapamycin-induced displacement of Raptor inhibits its
capacity to bind to and appropriately locate mTOR substrates and,
as such, they can no longer be phosphorylated (Figure 1).
Studies have implicated mTORC1 signaling in a range of
neural functions and neurological conditions including autism,
mental retardation, and epilepsy (Ehninger et al., 2008; Bourg-
eron, 2009), memory formation and brain plasticity (Hoeffer
and Klann, 2010), brain metabolism (Potter et al., 2010), feed-
ing behavior (Flier, 2006), as well as age-related neuropathologies
(Garelick and Kennedy, 2011). Rapamycin studies have directly
led to the ﬁnding that mTORC1 plays an important role in
activity-dependent translation of proteins required for synaptic
plasticity (i.e., long-term potentiation; Cammalleri et al., 2003)
and long-term depression (LTD; Mameli et al., 2007) by regulat-
ing the translation initiation complex through phosphorylation of
p70S6K and 4E-BP1. Indeed, there is strong evidence supporting a
role for mTORC1 in regulating the translation of a number of pro-
teins necessary for synaptic plasticity, such as Ca2+/Calmodulin-
dependent kinase II alpha (CamKIIα), AMPAR receptor subunits
(GluRs), microtubule-associated protein (MAP2), post-synaptic
density protein 95 (PSD-95), glutamate receptor interaction pro-
tein (GRIP1),andNMDARs, for example,GRIN1 (HouandKlann,
2004; Mameli et al., 2007).
Regulation of protein synthesis by downstream effectors of
mTORC1 generally occurs at the mRNA translation initiation step
and involves a complex array of initiation factors and binding
proteins working with the ribosomes to ensure that the mRNA
start codon is efﬁciently identiﬁed for the initiation of translation
(Sonenberg and Hinnebusch, 2007, 2009). An important compo-
nent of the translation initiation mechanism is the activation of
the mRNA by binding of the eIF4F complex to the mRNA’s 5′ cap.
mRNA activation through cap recognition is one way translation
is regulated and, thus, eIF4F binding constitutes a key regulatory
step. Regulation of eIF4F is under either direct or indirect con-
trol by mTORC1 (Hay and Sonenberg, 2004; Hoeffer and Klann,
2010). For example, mTORC1 phosphorylates 4E-BPs, a family of
translational repressor proteins, which leads to their dissociation
from eIF4E, enabling it to form the eIF4F complex for cap bind-
ing and participation in the initiation of translation of a range of
mRNAs (Gingras et al., 2004; Richter and Klann, 2009). mTORC1
can indirectly inﬂuence eIF4F activity through S6Kprotein kinases
that phosphorylate the ribosomal protein S6 and eIF4E, which in
turn increases mRNA translation (Raught et al., 2004). Therefore,
mTORC1-mediated phosphorylation of 4E-BPs and S6Ks leads to
increased translation of mRNA (Hay and Sonenberg, 2004; Richter
and Klann, 2009).
There is a second mTOR complex known as mTORC2 that
shares only three proteins in common with mTORC1 – that is,
mTOR, mLST8, and Deptor. The additional proteins making up
the mTORC2 complex include SAPK Interacting protein I (SIN1),
rapamycin-insensitive companion of mTOR (Rictor), and pro-
tein observed with Rictor (Protor). Unlike mTORC1, mTORC2
is insensitive to acute rapamycin treatment, although there are
reports that chronic treatment with the mTOR inhibitor may dis-
rupt mTORC2 complex formation (Sarbassov et al., 2006). Two
known targets of mTORC2 include the phosphorylation of AKT
(at Serine 473) and protein kinase Cα (Hay and Sonenberg, 2004;
Richter and Klann, 2009; Hoeffer and Klann, 2010). While the
role of mTORC1 complex in synaptic plasticity is well established,
recent studies have identiﬁed a potential molecular link between
mTORC2/AKT signaling and actin cytoskeletal remodeling, sug-
gesting a possible role in structural plasticity within the brain
(Sarbassov et al., 2004; Russo et al., 2009). Consistent with this
possibility, there is emerging evidence of an important role for
mTORC2 in promoting structural plasticity of VTA dopamine
neurons in response to opiates, which we outline in more detail
below (Mazei-Robison et al., 2011). Because the roles of mTORC2
in the brain are only beginning to be characterized, our primary
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FIGURE 1 | Schematic depicting mTORC1 signaling in a NAC a medium
spiny neuron with anterogradely transported BDNF being released
from aVTA dopamine neuron terminal and glutamate released from a
prefrontal cortex projection neuron. [Note however that BDNF can also
be released from PFC projection neurons]. A number of addiction-relevant
receptor systems including mGluRs and BDNF (but also dopamine and
ionotropic glutamate receptors), can signal via the phosphoinositide-3′
(PI3K) – AKT pathway to regulate mTOR activity. The recruitment of PI3K and
the production of phosphatidylinositol 3,4,5-trisphosphate (PIP3) elicits
3-phosphoinositide-dependent protein kinase 1 (PDK1) activity which in turn
phosphorylates AKT. AKT activation is then thought to lead to the
phosphorylation of tuberin (TSC2). Phosphorylation of TSC2 by AKT reduces
TSC1/2 activity and consequently increases mTOR activity; a process that is
thought to involve a Rheb-mediated inhibition of FKBP38 (or FKBP12 in the
brain, Hoeffer and Klann, 2010) – the latter being an inhibitory binding protein
that prevents mTOR complex 1 formation. FKBP12 prevents the binding of
the mTOR complex protein regulatory-associated protein with TOR (Raptor)
with the FRB binding domain through a process facilitated by rapamycin
(FKBP12-rapamycin). mTORC1 phosphorylates 4E-BPs, a family of
translational repressor proteins, which leads to their dissociation from
eIF4E, enabling it to form the eIF4F complex for cap binding and
participation in the initiation of translation of a range of mRNAs. Thus,
mTOR-mediated phosphorylation of 4E-BPs and S6Ks leads to increased
translation of mRNA – including transcripts that encode proteins required for
synaptic plasticity such as GluR1 AMPARs. Akt, also known as protein
kinase B; BDNF, brain-derived neurotrophic factor; ERK, extracellular
signal-regulated protein kinase; 4E-BPI, eukaryotic initiation factor
4E-binding protein; FKBP12, FK506-binding protein 12; Gq, Gq-protein;
mGluR, metabotropic glutamate receptor; mTOR, mammalian target of
rapamycin; NMDAR, N -methyl-D-aspartate receptor; PI3K,
phosphoinositide-3 kinase; PIKE, PI3K-enhancer; mTORC1, mTOR complex
1; PDK1, phosphoinositide-dependent kinase 1; PRAS40, proline-rich
Akt/PKB substrate 40 kDa; Raptor, regulatory-associated protein with TOR;
Rheb, Ras homolog enriched in brain; S6K, p70 S6 kinase; TrkB, tyrosine
receptor kinase B; TSC1/2, tuberous sclerosis complex 1 and 2; T, threonine;
P, phosphorylation.
focus will be the more established roles of mTORC1 and synaptic
plasticity and its relevance to addiction.
NEURAL MEMBRANE RECEPTORS UPSTREAM OF mTORC1
One pathway for mTORC1 activation in neurons involves neu-
rotrophin receptor signaling through receptor tyrosine kinases
in response to stimulation by trophic factors, e.g., BDNF. Tyro-
sine kinase B (TrkB) receptor activation by BDNF leads to
the activation of the phosphoinositide-3′ (PI3K)/AKT pathway
(Figure 1). Through a phosphorylation cascade, mTORC1 activ-
ity is increased by PI3K–AKT activation. The resultant increase
in mTOR activity is thought to occur through a Rheb-mediated
inhibition of FKBP38 (or FKBP12 in the brain;Hoeffer and Klann,
2010) – the latter being an inhibitory binding protein that pre-
vents mTOR complex formation. It is important to note, however,
that mTORC1 is actually at the “crossroads” of a number of
addiction-relevant signaling pathways that regulate the transla-
tion of synaptic proteins, and thus LTP and LTD in the brain
(Figure 1; Hoeffer and Klann, 2010). For example, in addition
to neurotrophins, the ionotropic N -methyl-d-aspartate (NMDA)
and alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid
(AMPA) receptors and dopamineD1,D2 receptors also can induce
mTORC1 activity (Hay and Sonenberg, 2004; Hoeffer and Klann,
2010). Particularly relevant to the present review, given their
well established role in addiction-related behaviors (Bird and
Lawrence, 2009; Jupp and Lawrence, 2010; Duncan and Lawrence,
2011), are ﬁndings that group I mGluRs can inﬂuence mTOR
activity and evokeLTD(Rong et al., 2003;Gong et al., 2006;Mameli
et al., 2007; Ronesi and Huber, 2008; Hoeffer and Klann, 2010;
Sharma et al., 2010). mGluR1/5s are linked to the enhancer of
PI3K (PIKE) by the Homer family of scaffold proteins and in the
hippocampus, recruitment of this pathway enhances PI3K→AKT
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phosphorylation and inducesmTOR activity and LTD (Rong et al.,
2003; Gong et al., 2006; Ronesi and Huber, 2008; Mameli et al.,
2009; Hoeffer and Klann, 2010; Sharma et al., 2010). It will be
important to determine if a similar mechanism regulates VTA and
NAC plasticity in response to addictive drugs.
Metabotropic glutamate receptor, TrkB, and NMDA receptors
can also increase the translation of synaptic proteins through the
extracellular-regulated kinase MAP kinase (ERK) pathway (Mao
et al., 2005; Banko et al., 2006; Gong et al., 2006; Page et al., 2006;
Gelinas et al., 2007). In fact, co-incidental activation of mTOR and
ERK may be necessary for the precise control of the translational
machinery that regulates changes in synaptic efﬁcacy (Gelinas
et al., 2007). Importantly though, it does appear that under some
circumstances mTOR activation alone is sufﬁcient for synaptic
protein translation and synaptic plasticity (Mameli et al., 2007;
Ronesi andHuber,2008).With respect to ERK’s involvement in the
control of translation and its interactionwithmTOR,ERK can also
inhibit tuberin (TSC2), and therefore inﬂuence mTOR activity.
Further, ERK can independently phosphorylate the same down-
streameffectors of translation thatmTOR targets, e.g., p70S6K and
4E-BP1, an effect that appears to be mediated by the recruitment
of MAPK-interacting kinase (Mnk1; Banko et al., 2004; Laplante
and Sabatini, 2009; Santini et al., 2009).
mTORC1’S ROLE IN SYNAPTIC PLASTICITY AND LONG-TERM
MEMORY FORMATION
This section aims to present a brief overview of the role of
mTORC1 in synaptic plasticity and memory formation as a pref-
ace to a discussion of the possible links between this role and
cocaine-induced plasticity impairments. Translation of synaptic
proteins in dendrites is thought to be an important mechanism for
altering synapse structure and function (Kandel, 2001; Bramham
and Wells, 2007). Early studies ﬁrst alluded to this by demon-
strating that dendrites contain the necessary substrates for protein
translation includingmRNA, ribosomes, and translation initiation
factors (Bodian, 1965; Torre and Steward, 1992; Crino and Eber-
wine, 1996; Tian et al., 1999; Aakalu et al., 2001; Asaki et al., 2003).
Importantly, these initial observations were consistent with func-
tional studies showing that late phase LTP (L-LTP) is dependent on
the transcription and synthesis of dendritic proteins,whereas early
phase LTP (E-LTP) relies on modiﬁcations to existing proteins
(Kandel, 2001). These studies reported effects on hippocampal
L-LTP and long-term facilitation in Aplysia (Brown et al., 1995;
Beretta et al., 1996; Casadio et al., 1999; Tang et al., 2002; Cam-
malleri et al., 2003). Subsequent studies by Cammalleri and Tang
demonstrated a post-synaptic co-localization of mTOR (and other
translation regulation factors such as 4E-BP1 and 2) with the
PSD-95, in dendrites of cultured hippocampal neurons. These
groups also provided evidence of activity-dependent changes in
the phosphorylation status of a number of key substrates within
this pathway (Tang et al., 2002; Cammalleri et al., 2003), linking
synaptic activity with phosphorylation of mTOR substrates.
Similar to L-LTP, long-term memory formation in intact ani-
mals also requires new protein synthesis. For example, broad-
spectrum protein synthesis inhibitors, such as anisomycin, affect
the consolidation and reconsolidation of fear memories (Schafe
et al., 1999; Nader et al., 2000; Schafe and LeDoux, 2000;
Parsons et al., 2006b). Importantly, behavioral studies employing
rapamycin support a role for mTORC1 signaling in long-term
memory formation. Accordingly, systemic rapamycin treatment
suppresses reconsolidation of fearmemory inmice (Blundell et al.,
2008), and when injected into the auditory cortex, the mTOR
inhibitor was found to block long-term fear memory consolida-
tion (Tischmeyer et al., 2003). Rapamycin delivered into speciﬁc
brain sites such as the amygdala or hippocampus also suppresses
the consolidation and reconsolidation of fear memories (Parsons
et al., 2006a), indicating a widespread role for mTORC1 in synapse
function.With respect to the speciﬁc complement of synaptic pro-
teins that are regulated by mTORC1 and are required for learning
in these paradigms, Parsons et al. (2006a) showed that intra-
amygdala rapamycin reduced fear learning to a similar extent to
anisomysin. However, while anisomycin reduced protein synthesis
by an estimated 60–80%, rapamycin reduced protein synthesis by
only 10%. These ﬁndings were taken to indicate that only a speciﬁc
subset of proteins, controlled by mTORC1, are required and fun-
damental to the learning processes responsible for fear memory
(Parsons et al., 2006a).
While most animal studies using rapamycin support a role for
mTORC1 in long-term memory formation, Panja et al. (2009)
found that whereas rapamycin inhibited hippocampal L-LTP
in vitro, the mTOR inhibitor failed to block L-LTP in vivo (Panja
et al., 2009). Studies using mice possessing genetic manipulations
of molecules that increase mTORC1 activity have also demon-
strated inconsistent results with respect to synaptic plasticity and
long-term memory formation (see Stoica et al., 2011 supplemen-
tary data for review). Importantly, in a comprehensive set of
experiments conﬁrming the importance of mTORC1 in synaptic
plasticity, Stoica et al. (2011) recently reported that mTOR het-
erozygote mice (mTOR+/−) display normal L-LTP and long-term
memory formation (Stoica et al., 2011). However, a sub-threshold
dose of rapamycin, ineffective in reducing LTM and L-LTP in wild
type mice, signiﬁcantly reduced these parameters in mTOR+/−
animals.
It is also noteworthy, given the now well-characterized role for
BDNF in neuroadaptations associated with drug addiction (see
further discussion below), that BDNF-induced LTP is blocked
by rapamycin in the hippocampus and that this process requires
new protein synthesis (Tang et al., 2002). Interestingly, Slipczuk
et al. (2009) demonstrated that BDNF activates mTOR and reg-
ulates inhibitory avoidance memory formation (Slipczuk et al.,
2009). This process was found to involve an mTORC1-dependent
upregulation of GluR1 AMPARs. These data are consistent with
other studies describing BDNF/mTORC1-dependent increases in
synaptic plasticity proteins including PSD-95, GluRs, and other
plasticity-associated proteins (Schratt et al., 2004; Page et al., 2006;
Mameli et al., 2007). It will be interesting to determine the role of
BDNF in driving mTORC1-dependent processes in brain regions
known to be involved in addiction.
PUTATIVE ROLE FOR mTORC1 IN ADDICTION-RELEVANT
SYNAPTIC PLASTICITY
Maladaptive behaviors that are characteristic of addiction are
underpinned by persistent changes in synaptic properties, par-
ticularly in the brain reward pathways.
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As discussed above, activation of a number of receptor sys-
tems that can produce synaptic plasticity, including TrkB, NMDA,
Group I mGluRs, and DRs have been shown to activate the
mTORC1 pathway and are implicated in the neurobiological
processes that lead to the usurpation of the VTA–NAC pathway
during the addiction process (Kalivas, 2009; Kalivas and Volkow,
2011).
With respect to drug-induced plasticity in the VTA, Mameli
et al. (2007) showed that cocaine-evoked LTP was reversed by
pharmacological stimulation of mGluR1 receptors using (RS)-3,5-
dihydroxyphenylglycine (DHPG), an mGluR1/5 agonist. Notably,
this effect involvedmTORC1-dependent synthesis and subsequent
insertion of Ca2+ impermeable GluR2AMPAR subunits. Interest-
ingly, although there is known to be signiﬁcant crosstalk between
ERK and mTORC1 signaling pathways, the ERK inhibitor U0126
had no effect on mGluR1-induced LTD in cocaine-exposed ani-
mals. Subsequent studies have implicated an mGluR1–Homer
interaction in the LTD that appears protective, at least initially,
against cocaine-induced potentiation of excitatory inputs on VTA
dopamine neurons. The resultant potentiation of excitatory inputs
onto VTA dopamine neurons during the early stages of cocaine
self-administrationwas found to be necessary for subsequent plas-
ticity changes within the NAC (Mameli et al., 2009) and the later
expression of addiction behaviors including reinstatement, i.e.,
“relapse” (see Box 1 – descriptions). These ﬁndings have led to
the hypothesis that exhaustion of mGluR and mTOR-dependent
LTD in midbrain dopamine neurons may predispose addiction-
vulnerable animals to deﬁcits in plasticitywithin theNAC(Luscher
and Huber, 2010).
While it is unclear if striatal synaptic plasticity also involves an
mTORC1-dependent process (Luscher and Huber, 2010), drug-
induced maladaptation of Group I mGluR, and Homer signaling
are linked with impairments in the ability to evoke LTD in the
NAC (Martin et al., 2006; Moussawi et al., 2009). Indeed, experi-
menter or self-administered cocaine reduces both mGluR1/5 and
Homer1b/c levels in the NAC (Szumlinski et al., 2006) and the
recovery of LTD at cortico-accumbal synapses in cocaine-trained
rats appears to be dependent on restoring tone to mGluR5 recep-
tors (Moussawi et al., 2009). As highlighted above, an important
role formGluR1/5 receptors andHomer in the induction of synap-
tic plasticity now exists and there is substantial evidence linking
this signaling complex to the regulation of extracellular glutamate
levels in the NAC and the disruption of glutamate homeostasis
after chronic drug taking (Szumlinski et al., 2004,2008;Kalivas and
Volkow, 2011). Interestingly therefore, Ronesi and Huber (2008)
have linked LTD in the hippocampus to a Homer/mGluR1/5 inter-
action that requires mTOR but not ERK. It will be interesting to
determine if the loss of LTD seen at cortico-accumbal synapses
after chronic cocaine exposure may involve a dysregulation of
Homer/mGluR1/5→mTOR pathway.
SIGNALING MOLECULES UPSTREAM OF mTORC1 THAT ARE
IMPLICATED IN DRUG-MOTIVATED BEHAVIORS
The ﬁrst evidence that mTORC1 signaling might play a role
in addiction came from the demonstration that rapamycin
infused into the NAC of male Sprague Dawley rats prevented
psychostimulant-induced sensitization of methamphetamine
place preference – a behavior shown to require structural plastic-
ity in the striatum (Narita et al., 2005). These authors also showed
that methamphetamine administration activated the downstream
target of mTOR, p70S6K in the NAC (Narita et al., 2005). Con-
sistent with the methamphetamine ﬁndings, Szumlinski et al.
recently showed that systemic rapamycin (10mg/kg) suppressed
the expression of cocaine-induced place preference (cpp) in
C57/B6 mice (see Box 1; Bailey et al., 2011). Intriguingly, while the
expression of CPP was found to be rapamycin sensitive, the devel-
opment of cocaine sensitization or CPP was not affected by prior
treatment with the mTOR inhibitor (Bailey et al., 2011). In con-
trast, Wu et al. (2011) showed that rapamycin dose dependently
suppressed the development of cocaine sensitization and CPP in
female rats (Wu et al., 2011). It will be important to determine if
these differences are related to sex or species differences.
A number of cell membrane receptor signaling molecules
that can inﬂuence mTOR have been implicated in the neu-
roadaptations that control psychostimulant-motivated behav-
iors using experimenter-administered drug exposure procedures
(Russo et al., 2007, 2009; McGinty et al., 2008; Shi and McGinty,
2011). Noteworthy is the well-characterized psychostimulant-
induced changes to BDNF/TrkB receptor pathway in the VTA and
NAC, making this system a strong candidate for drug-induced
mTORC1 activation (Narita et al., 2003; Russo et al., 2009; Ghitza
et al., 2010; McGinty et al., 2010). It is also important to note that
changes in BDNF/TrkB signaling is not limited to psychostimu-
lants, with studies implicating this neurotrophic factor in opiate-
(Russo et al., 2007) and alcohol-motivated behaviors (Moonat
et al., 2010). With respect to psychostimulant-induced BDNF
changes, mRNA and protein levels for this neurotrophic factor are
altered in response to experimenter-administered cocaine injec-
tions (Zhang et al., 2002; Le Foll et al., 2005) and Bdnf+/1 mice are
more hyperactive than wildtypes to psychostimulant injections
(Saylor and McGinty, 2008). Furthermore, BDNF protein infused
into the NAC or VTA enhances cocaine-induced locomotor activ-
ity (Horger et al., 1999; Hall et al., 2003). More recently, Lobo et al.
(2010) employed a genetic and optogenetic approach to assess the
role of BDNF/TrkB signaling in D1 versus D2 receptor-expressing
medium spiny neurons (MSNs) in cocaine-motivated behaviors.
To achieve this they used D1 or D2-Cre-ﬂoxedTrkB mice, in which
the TrkB receptor is selectively deleted in D1 versus D2 MSNs.
Interestingly, D1-Cre-ﬂoxedTrkB mice showed enhanced cocaine-
motivated behaviors, including CPP, whereas the opposite behav-
ioral effects were observed inD2-Cre-ﬂoxedTrkBmice (Lobo et al.,
2010). These data were further probed by expressing the blue light
sensitive (∼470 nm) cation channel, channelrhodopsin-2 (ChR2),
in D1 or D2 MSN populations by NAC-directed injections of a
Cre-inducible adenovirus DIO-AAV. Optical activation of ChR2,
which caused depolarization in D1 or D2 MSNs, recapitulated the
cocaine-induced increase or decrease in place preference displayed
by D1 or D2-Cre–ﬂTrkB mice respectively, providing complemen-
tary support for differential roles for BDNF inD1 versusD2MSNs.
These data highlight the need to better understand the contribu-
tions of speciﬁc signaling pathways to drug-induced plasticity in
these sub-populations of striatal neurons.
Signaling molecules that inﬂuence mTOR activity and are
downstream of addiction-relevant cell membrane receptors such
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Box 1 Glossary terms/definitions – cited within text.
Conditioned place preference (CPP): animals are conditioned to sides of an experimental chamber that have different contextual cues –
e.g., the walls and or ﬂoors are made of different materials. An experimenter injects saline or drug intraperitoneally (i.p.), before placing
the mouse or rat into designated sides of the compartment. The animal’s preference for the drug-paired versus saline paired side (CPP) is
assessed in a subsequent test, performed under drug free conditions. This procedure is thought to involve Pavlovian conditioning.
Psychomotor sensitization: a progressive increase (reverse tolerance) to a drug’s locomotor activating effects that is usually induced by
a single unit dose of drug injected by the experimenter over 5–10 days. The expression of locomotor sensitization is often assessed during
withdrawal after an acute injection of the drug (an equivalent dose is used to that given during the induction phase).
Drug self-administration: animals are trained to lever press in operant responding chambers for a unit dose of drug (or natural reward,
e.g., sucrose). Using this procedure animals can learn to regulate their own drug intake and depending on the type of schedule, behaviors
such as motivation to lever press can be assessed. This is achieved by increasing the ratio, i.e., the number of lever presses required to
receive a drug infusion or reward (a progressive ratio schedule).
Reinstatement (relapse-like behavior): amethod to gage the propensity to seek and consume drug that employs drug cues that have been
associated through classical conditioning procedures during the drug taking phase, stress (most commonly footshock), or small priming
doses of drug to “reinstate” lever pressing after a period of extinction training. After training animals to lever press for drug the animals are
subjected to a period of forced abstinence during which they are re-exposed to the operant chamber but lever pressing is not reinforced
with drug infusions. Once a pre-determined extinction period or an extinction criterion is met, the animals are exposed to drug cues, stress,
or priming doses of drug and reinstatement is assessed. Importantly, this tests occurs in the absence of subsequent drug reward. Recovery
of responding can also be tested after periods of abstinence without extinction training.
Two-bottle free choice: used to assess alcohol drinking behaviors. Two bottles are place in equivalent areas within the home cage and
are ﬁlled with water and water combined with the test concentration of alcohol – commonly 5–20%. Alcohol preference is determined by
comparing the weight or volume of liquid consumed. Blood alcohol concentrations are often used to verify that the animals are exposed to
the drug.
asTrkB,NMDARs,mGluRs,andDRs (Figure 1),havebeendirectly
implicated in drug-induced modiﬁcation of behavioral output.
For example, in the case of PI3K, Izzo et al. (2002) reported
that the inhibitor LY294002 suppressed the expression, but not
the induction, of cocaine-sensitization (Izzo et al., 2002). Fur-
ther, p85a/p110 PI3K activity is observed within the shell of the
NAC during cocaine sensitization and systemic injections of the
dual D1/D2 receptor agonist pergolide suppressed cocaine sen-
sitization and the concomitant increase in PI3K activity (Zhang
et al., 2006). In the case of AKT, psychostimulants produce an
initial increase in phosphorylation of this kinase through a D1-R-
dependent mechanism, however at later time points, AKT activity
decreases through an effect that is thought to involve D2-R acti-
vation. It should be pointed out that much of this work relates to
the dorsal striatum (Brami-Cherrier et al., 2002; Beaulieu et al.,
2004, 2005, 2006; Shi and McGinty, 2007, 2011; McGinty et al.,
2008). An involvement for AKT in drug-induced neuroadapta-
tions extends to opiates, as Russo and co-workers have also shown
that exposure to morphine decreases AKT phosphorylation in the
NAC and VTA (Mueller et al., 2004). Furthermore, this group
implicated AKT pathway in morphine induced structural adapta-
tions in VTA dopamine neurons, with these effects being linked
with opiate tolerance and escalation of drug taking (Russo et al.,
2007). Interestingly, a very recent study from this group found
that a decrease in mTORC2/AKT signaling was responsible for
the opiate-induced neuroadaptations to dopamine neurons.Alter-
ations in mTORC1-associated molecules were also observed in
this study, however these changes were in the opposite direction
to mTORC2 and independent of the opiate-induced structural
changes to VTA dopamine neurons. Understanding the crosstalk
between these systems and the relevance of increased mTORC1
signaling to opiate-induced synaptic plasticity would seem highly
relevant given the work of Mameli et al. (2007) discussed above.
Much previous work, in terms of downstream effectors of
addiction-relevant receptor systems, has centered on the ERK
pathway (Valjent et al., 2000, 2004, 2005; Girault et al., 2007).
Particularly relevant to the present review, ERK has been shown to
contribute to l-DOPA-induced activation of mTORC1, an effect
assumed to occur through phosphorylation of TSC2 or Raptor
(Santini et al., 2009). It will be for future work to determine which
of these systems (see Figure 1) signal to mTOR in response to
drug exposure and if co-incidental activation of these pathways
is responsible for the full expression of drug-induced behavioral
output (Gelinas et al., 2007; Girault et al., 2007). Importantly, the
data discussed above demonstrate an important involvement of
upstream regulators of mTOR in drug-motivated behaviors.
EVIDENCE ARISING FROM STUDIES UTILIZING
SELF-ADMINISTRATION DRUG EXPOSURE PROCEDURES
Strongly supporting the predicted role for mTORC1 in addic-
tion, Shi et al. (2009) showed that in a small-randomized control
study, acute systemic rapamycin (2.5 or 5mg) suppressed cue-
induced drug craving in abstinent heroin addicts (Shi et al., 2009).
In light of this ﬁnding, it is interesting that several recent reports
using drug self-administration models, a method of drug expo-
sure that has signiﬁcantly greater face validity to human drug
taking than experimenter-administered modes, also support a role
for mTORC1 in addiction. First, Neasta et al. (2010) showed that
phosphorylatedmTORC1andp70S6K (but interestingly not ERK)
is increased after binge alcohol exposure using two-bottle free
choice and operant alcohol self-administration procedures (see
Box 1). The mTORC1 signaling pathway induction observed by
Neasta et al. (2010) was accompanied by increases in the synaptic
proteins, Homer and GluR1 AMPAR subunits in the NAC. Pre-
treatment with rapamycin prevented the increase in Homer. Con-
sistent with systemic rapamycin injections, intra-NAC rapamycin
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injections also reduced alcohol-motivated behaviors, including
self-administration and extinction responding. In a follow-up
study, these authors showed that pharmacological inhibition in the
NACof signaling substrates upstreamof mTORC1 also suppressed
alcohol drinking. Thus, the PI3K inhibitor wortmannin, or tri-
ciribine, an AKT inhibitor, reduced alcohol-motivated behaviors
in both mice and rats, including binge drinking and operant alco-
hol self-administration. Notably, these manipulations were found
to have no effect on water or sucrose self-administration.
In studies speciﬁcally designed to test the role of mTORC1
signaling in cocaine-seeking and relapse-like behavior, Lu et al.
(2006) infused rapamycin into the core of the NAC of rats 30min
prior to cue-induced reinstatement testing (Wang et al., 2010).
The mTORC1 inhibitor signiﬁcantly reduced cocaine- but not
sucrose-reinstatement. Interestingly, unlike its effects on alco-
hol drinking in mice, rapamycin had no effect on cocaine self-
administration, suggesting a differential role for mTORC1 in
psychostimulant versus alcohol reinforcement. These authors also
indicated that rapamycin blocked an NMDA receptor-induced
potentiation of cocaine-seeking and recruitment of the mTORC1
pathway. These data indicate a potential regulatory pathway ini-
tially involving NMDA receptor activation, at least in the processes
acutely regulating relapse behavior.
In a recent study aimed at identifying putative molecular sub-
strates that are responsible for the development of addiction and
relapse vulnerability, we phenotyped rats using criteria derived
from the Diagnostic and Statistical Manual for Substance Depen-
dence (DSM-IV;Brownet al., 2011) – similar toDeroche-Gamonet
and colleagues’ behavioral approach ﬁrst published in 2004. The
behavioral tests that were applied at different time points across
the addiction cycle (Deroche-Gamonet et al., 2004) included: (i)
testing for an animals’ ability to refrain from drug taking during a
signaled period of drugnon-availability; (ii) testing themotivation
to take the drug by progressive ratio testing (Deroche-Gamonet
et al., 2004); (iii) testing for relapse vulnerability using a cue-
induced reinstatement procedure. To be phenotyped as addiction–
vulnerable, animals were required to score within the top 40%
of the cohort for reinstatement responding and the top third of
the distribution for the two other vulnerability markers that were
assessed at earlier points in the addiction cycle, i.e., motivation
to lever press on a progressive ratio schedule for cocaine and the
ability to refrain fromdrug taking during a period of signaled non-
drug availability (NDA), the latter being a presumptive test of com-
pulsive drug-seeking. Twenty-four hours after relapse testing, ani-
mals were sacriﬁced, and gene expression for synaptic plasticity-
associated transcripts was assessed using qPCR in the ventral and
dorsal striatum. Interestingly, compared to resistant animals, rats
classiﬁed as addiction, and relapse vulnerable displayed reduced
gene expression for a number of plasticity-associated transcripts,
including mTOR, activity-regulated cytoskeletal protein (Arc),
Group I mGluRs, GluR subunits, and DRs. Importantly, ani-
mals that were separated into vulnerability groups did not differ
in terms of their total cocaine intake across the testing period,
suggesting that the effects on gene expression are likely to relate
to neural processes underpinning the development of addiction,
rather than drug-effects alone. In ongoing studies in our labo-
ratory, we have also found that intra-NAC rapamycin reduced
progressive ratio break points in cocaine-trained rats and lever
pressing during NDA periods. Remarkably, intra-NAC rapamycin
infusions also suppressed cue-induced reinstatement 6–8weeks
after treatment and this behavioral effect was associated with a
reduction in p70S6K expression at this time point (Manuscript in
preparation).
The reduced gene expression we observed for mTOR mRNA
in the NAC of addiction and relapse vulnerable rats may ini-
tially seem at odds with the effects of systemic or intra-cranial
injections of rapamycin on drug-motivated behaviors described
above. One possible explanation for this apparent discrepancy is
that increased activity within the mTORC1 signaling pathway may
have manifested in addiction/relapse vulnerable animals as down-
regulated mTORC1 transcript expression at the ﬁnal point of the
addiction cycle, i.e., 24 h after relapse test, corresponding with
when the brains were harvested. Post-transcriptional repression
by microRNAs or other epigenetic regulators may lead to a feed-
back inhibition of mTORC1 mRNA synthesis in attempt to limit
the cocaine-induced increase in mTORC1 activity. In this regard,
it is interesting that several recent studies have demonstrated an
important role for epigenetic changes which appear to regulate
the neural process that control the motivation to consume cocaine
(Kumar et al., 2005; Hollander et al., 2010; Im et al., 2010).
The exact cellular and molecular changes that are regulated
by mTORC1 and contribute to relapse vulnerability after with-
drawal and extinction training are yet to be determined. However,
the role of mTORC1 in relapse vulnerability may be related to
its involvement in the translation of synaptic proteins during
withdrawal. Indeed, one of the most consistently reported post-
synaptic changes in theNAC (andVTA) that is linkedwith elevated
relapse vulnerability is increased expression and signaling through
glutamatergic, excitatory AMPARs (Mameli et al., 2007, 2009;
Anderson et al., 2008; Conrad et al., 2008; Wolf and Ferrario,
2010).Cornish andKalivas published theﬁrst clear evidencepoint-
ing to a role for AMPARs in drug-seeking, showing that AMPA
receptor antagonists infused in the NAC suppress cocaine rein-
statement (Cornish et al., 1999; Cornish and Kalivas, 2000). More
recent studies have conﬁrmed and extended these important initial
ﬁndings by showing that it is an incorporation of GluR1 (Gria1)
subunits into AMPARs during withdrawal that triggers relapse-
like behavior (Anderson et al., 2008; Conrad et al., 2008). These
studies showed that injections into the NAC of a speciﬁc antago-
nist of the GluR1 subunit (1-naphthylacetylsperimine), or a viral
vector that prevents the transport of GluR1s for insertion into
the synaptic membrane, decreased relapse-like behavior (Ander-
son et al., 2008; Conrad et al., 2008). Importantly, propensity
to relapse was dependent on an increase in surface, intracellu-
lar, and total GluR1 levels (and not other GluR subunits). The
increase in both“pools”of GluR1s is consistent with a requirement
for production/translation of new rather than a redistribution of
old/existing GluR1s (Anderson et al., 2008; Conrad et al., 2008).
Electrophysiological studies conﬁrmed these biochemical changes
in NAC tissue are accompanied by alterations in the ﬁring proper-
ties of NAC MSNs. Thus, a “pathological” drive to increase GluR1
AMPA subunits during withdrawal appears to be fundamental
to increased vulnerability for relapse. Consistent with these data
are reports of impairments in the ability to evoke LTP or LTD in
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the NAC of animals with a clinically relevant history of cocaine
self-administration (Martin et al., 2006; Moussawi et al., 2009;
Kasanetz et al., 2010). Indeed, using the behavioral procedure out-
lined above to identify addiction–vulnerable animals, Kasanetz
et al. (2010) showed that impairments in the ability to evoke LTD
only persist in animals classiﬁed as addiction vulnerable (Kasanetz
et al., 2010).
It is interesting in light of evidence presented above that drug
self-administration models and relapse procedures have identi-
ﬁed an important role for striatal BDNF in addiction and relapse
vulnerability (Grimm et al., 2003) and that BDNF drives GluR1
AMPARs through anmTORC1-dependent process (Slipczuk et al.,
2009). Indeed, as described above, the BDNF→PI3K→AKT
pathway is a “prototypic” regulator of mTORC1 (Laplante and
Sabatini, 2009). Thus, it is plausible that BDNF drives mTOR
during early phases of the addiction cycle and that this chroni-
cally upregulates mTOR activity over time. Somewhat consistent
with this proposal, Graham et al. (2007) reported that cocaine
self-administration and the effort rats are willing to exert to
obtain cocaine is increased after repeated intra-NAC infusions of
BDNF. Thismanipulation also increased relapse vulnerability after
extinction training (Graham et al., 2007). Importantly, given the
potential supra-physiological effects of this manipulation, anti-
sera raised against BDNF produced opposing results. BDNF also
appears to drive addiction-relevant maladaptations in the dorsal
striatum (Im et al., 2010) and we found a strong trend for reduced
mTORexpression in global dissections of this brain region (Brown
et al., 2011). Whether BDNF inﬂuences striatal mTOR activity in
cocaine-trained rats is yet to be assessed.
Is important to note that the role of BDNF in drug-motivated
behaviors, particularly drug-seeking, is both drug- and brain
region-dependent (McGinty et al., 2010). Thus, infusions of BDNF
in the PFC have opposite effects to striatal injections on cocaine-
seeking (Berglind et al., 2007, 2009; McGinty et al., 2010), with
these effects shown to be linked with normalization of basal
extracellular glutamate release in the NAC. Interestingly, the sup-
pressive effect of intra-PFC BDNF on reinstatement appears to
depend on MAPK/ERK signaling (and not PI3K), as infusions of
a MEK1/2 inhibitor U0126 prevent the suppression of cocaine-
seeking produced by BDNF. It will be important for future studies
to determine whether the reductions in drug-seeking after intra-
PFC BDNF injections are accompanied by changes in PFC mTOR
(Whitﬁeld et al., 2011). These studies also highlight the importance
of understanding the role for signaling pathways downstream
of BDNF at time points across the addiction cycle to deter-
mine whether changes in MAPK/ERK or PI3K pathways are brain
region- and/or addiction cycle-dependent.
CONCLUSION: POTENTIAL CLINICAL UTILITY OF mTORC1
INHIBITION
In the present review we have summarized the current under-
standing of the role of the mTORC1 signaling pathway in the
development of addiction and relapse vulnerability. The ultimate
goal of understanding the complexmolecular signaling events that
controls protracted addiction and relapse behaviors is to identify
possible targets for treatments for this condition. It is interesting
in this regard that mTORC1 inhibition reduces craving in heroin
addicts; albeit in small study involving acute rapamycin treatment
(Shi et al., 2009). Also, chronic rapamycin increased lifespan in
both male and female mice (Harrison et al., 2009) and rapamycin
is approved for use in humans for the treatment of renal cell car-
cinoma (Bhatia and Thompson, 2009). It should be mentioned
that recent reports indicate that chronic rapamycin can produce
weight loss and new onset diabetes (Johnston et al., 2008; Deblon
et al., 2011).
Despite thepromisingpre-clinical data using the animalmodels
of addiction that we have outlined above, a number of important
questions remain to be answered with regards to the role of mTOR
in the addiction process and CNS processes more generally. Below
we will outline a number of knowledge gaps that, when ﬁlled,may
progress our understanding of the importance of mTORC1 signal-
ing toward this end. It is important to point out that regardless of
the potential clinical utility of mTORC1 inhibition, pharmacolog-
ical agents targeting this pathway are likely to serve as important
tools for identifying the critical subset of synaptic proteins that
are responsible for neuroadaptations underpinning addiction and
relapse vulnerability and brain plasticity more broadly.
A full understanding of the involvement of mTOR in the
addiction process will require a comprehensive assessment of the
changes within the mTOR signaling pathway across the addiction
cycle. Using addiction phenotyping strategies to identify vulnera-
ble animals at early and late stages of the addiction cycle, including
into withdrawal, would improve our understanding of how this
system becomes engaged and contributes to the processes that
increase synaptic proteins critical for relapse. It will also be impor-
tant to assess changes in the mTOR pathway in other addiction-
relevant brain areas such as the PFC and amygdala. This review
highlights BDNF as being a possible mediator of drug-induced
mTOR activity, however, as has also been made clear through-
out this review, other receptor systems (e.g., NMDA,mGluRs, and
DRs) can also regulatemTORactivity and synaptic protein transla-
tion through parallel signaling pathways. Thus, it will be necessary
to determine the likely interactions between PI3K →AKT and
alternative signaling pathways that appear to exhibit crosstalk with
mTOR in initiating plasticity-associated protein translation (e.g.,
ERK). In addition, although this review has focused on mTORC1,
mTORC2 has recently been identiﬁed as playing an important
role in opiate-induced structural plasticity (Mazei-Robison et al.,
2011). In the striatum, it will be important to determine whether
mTOR expression is restricted to speciﬁc cell types within the
NAC, as appears to be the case for psychostimulant-induced
ERK expression (Valjent et al., 2005). Preliminary studies in this
regard indicate that dopamine agonists may speciﬁcally increase
mTOR in MSNs that express dopamine-1 receptors (Santini et al.,
2009).
Current data implicating mTORC1 in addiction has relied
primarily on acute pharmacological inhibition of mTOR using
rapamycin. Determining whether chronic treatment of animals
with rapamycin and other speciﬁc inhibitors of mTOR can sup-
press addiction and relapse-like behavior without producing “off-
target” effects will be required. Addiction studies would bene-
ﬁt from the use of genetic manipulations of key components
of the mTOR pathway. Unfortunately, mTORC1 knockout mice
are lethal and genetic manipulations of upstream effectors have
Frontiers in Pharmacology | Neuropharmacology February 2012 | Volume 3 | Article 13 | 8
Dayas et al. Role of mTOR in addiction vulnerability
produced conﬂicting results in terms of synaptic plasticity and
learning. Use of a pharmacogenetic approach similar to Stoica
et al. (2011) could circumvent this problem. It would be inter-
esting to utilize this approach in animal models of addiction to
assess behavioral and functional effects, e.g., LTP and LTD in NAC
and VTA.
In conclusion, the present review has outlined the recent evi-
dence that mTORC1 signaling is involved in the development and
expression of addiction behaviors. To this end we have discussed
the role of mTOR in synaptic protein translation in the context
of known addiction-associated signaling molecules. Further work
will be required to determine the exact role of mTOR in the addic-
tion process and whether members of this signaling pathway will
prove to be appropriate targets for medications development to
reduce relapse addiction and risk.
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